The TNF inhibitor golimumab (Simponi) will be available on the PBS for the treatment of non-radiographic axial spondyloarthritis from 1 December. The move, following a positive recommendation from the PBAC, will allow up to 4000 patients with spondyloarthritis to receive subsidised treatment with a biologic early in the course of the disease before it progresses ...
Golimumab gets PBS listing for nr-axSpA
By Michael Woodhead
9 Oct 2018